Silence Therapeutics Secures $2M Milestone Payment
Company Announcements

Silence Therapeutics Secures $2M Milestone Payment

Silence Therapeutics (SLN) has released an update.

Silence Therapeutics, a biotech firm specializing in RNA interference for disease treatment, has received a $2 million payment from Hansoh Pharma upon reaching a key research milestone. This payment is part of a larger collaboration that could yield Silence up to $1.3 billion in various milestones, along with royalties on product sales. The partnership, which began in October 2021, leverages Silence’s mRNAi GOLD™ platform to develop siRNAs targeting genetic diseases, marking the fourth research milestone achieved to date.

For further insights into SLN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlySilence Therapeutics files automatic ordinary shares offering
TheFlyAstraZeneca deal has positive read for Silence Therapeutics, says Morgan Stanley
TheFlyAstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App